Metastatic Pancreatic Cancer With George P. Kim, MD, and Eileen M. O'Reilly, MD: Case 2
EP. 1: George P. Kim, MD: Aligning Treatment With Updates in NCCN Guidelines
September 23rd 2016
EP. 2: George P. Kim, MD: Expected Response with Liposomal Irinotecan
September 23rd 2016
EP. 3: George P. Kim, MD: Role of Liposomal in Nanoliposomal Irinotecan
September 23rd 2016
EP. 4: George P. Kim, MD: Importance of CA19-9 and Albumin Markers
September 23rd 2016
EP. 5: George P. Kim, MD: Options for Patient Going Forward
September 23rd 2016
EP. 6: George P. Kim, MD: Impact of Effective Therapies on Treatment
September 23rd 2016
EP. 7: Eileen M. O'Reilly, MD: Aligning Treatment With Updates in NCCN Guidelines
September 23rd 2016
EP. 8: Eileen M. O'Reilly, MD: Expected Response with Liposomal Irinotecan
September 23rd 2016
EP. 9: Eileen M. O'Reilly, MD: Role of Liposomal in Nanoliposomal Irinotecan
September 23rd 2016
EP. 10: Eileen M. O'Reilly, MD: Importance of CA19-9 and Albumin Markers
September 23rd 2016
EP. 11: Eileen M. O'Reilly, MD: Options for Patient Going Forward
September 23rd 2016
EP. 12: Eileen M. O'Reilly, MD: Impact of Effective Therapies on Treatment
September 23rd 2016
